Tisotumab Vedotin

Summary

Tisotumab Vedotin (CHEMBL4297841) is an approved antibody drug conjugate (ATC L01FX23) targeting F3; indicated across 6 conditions including neoplasm and peritoneal neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody drug conjugate
• ATC class: L01FX23
• Targets: 1 (F3)
• Indications: 6 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297841
Name	Tisotumab Vedotin
Type	Antibody drug conjugate
Max phase	4
ATC	L01FX23

Also known as: Humaxtfadc, HuMax-TF-ADC, Tisotumab vedotin, Tisotumab vedotin tftv, Tisotumab vedotin-tftv, Tisotumab vedotina, Tisotumab vedotine, Tivdak, TISOTUMAB VEDOTIN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
F3	coagulation factor III, tissue factor	Binding		5.5%	P13726

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): F3.

Top Reactome pathways

11 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	F3
R-HSA-140834	1	F3
R-HSA-140877	1	F3
Signal Transduction	1	F3
Signaling by NTRKs	1	F3
Signaling by NTRK1 (TRKA)	1	F3
Nuclear Events (kinase and transcription factor activation)	1	F3
Signaling by Receptor Tyrosine Kinases	1	F3
NGF-stimulated transcription	1	F3
Initiation of coagulation cascade	1	F3
Regulation of clotting cascade	1	F3

Dominant GO biological processes

GO term	Targets
positive regulation of endothelial cell proliferation	1
activation of plasma proteins involved in acute inflammatory response	1
activation of blood coagulation via clotting cascade	1
blood coagulation	1
positive regulation of gene expression	1
positive regulation of platelet-derived growth factor receptor signaling pathway	1
protein processing	1
cytokine-mediated signaling pathway	1
positive regulation of cell migration	1
positive regulation of TOR signaling	1
positive regulation of interleukin-8 production	1
positive regulation of angiogenesis	1
positive regulation of positive chemotaxis	1
positive regulation of endothelial cell apoptotic process	1
response to stress	1

Indications & clinical

Indications

6 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
ovarian cancer	2	MONDO:0008170	MONDO:0008170

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	2
PHASE1/PHASE2	2
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06952660	PHASE4	RECRUITING	Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT06459180	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT04697628	PHASE3	COMPLETED	Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT03485209	PHASE2	ACTIVE_NOT_RECRUITING	Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03245736	PHASE2	COMPLETED	Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
NCT03438396	PHASE2	COMPLETED	A Trial of Tisotumab Vedotin in Cervical Cancer
NCT03657043	PHASE2	COMPLETED	A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
NCT03786081	PHASE1/PHASE2	TERMINATED	Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
NCT03913741	PHASE1/PHASE2	COMPLETED	A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
NCT05866354	PHASE1	COMPLETED	To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

10 molecules share ≥1 primary target. Top 10 by shared-target count:

Molecule	Source	Status	Shared targets
NIACINAMIDE	ChEMBL	Phase 4 (approved)	F3
ICOSAPENT	ChEMBL + PubChem	Phase 3 (approved)	F3
CURCUMIN	ChEMBL	Phase 3	F3
ENTINOSTAT	ChEMBL	Phase 3	F3
GAMOLENIC ACID	ChEMBL	Phase 3	F3
DIHOMO-GAMMA-LINOLENIC ACID	ChEMBL	Phase 2	F3
LINOLEIC ACID	ChEMBL	Phase 2	F3
OLEIC ACID	ChEMBL	Phase 2	F3
TETRAHYDROPALMATINE	ChEMBL	Phase 2	F3
Valproic Acid	PubChem	Approved	F3